Effect of an oral absorbent AST-120 in late-stage chronic kidney disease (CKD) patients

Trial Profile

Effect of an oral absorbent AST-120 in late-stage chronic kidney disease (CKD) patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 May 2014

At a glance

  • Drugs Charcoal (Primary) ; Methoxy polyethylene glycol-epoetin beta
  • Indications Renal failure
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 May 2014 New trial record
    • 08 Apr 2014 Primary endpoint 'Renal-function' has been met.
    • 08 Apr 2014 Results published in the Nephrology Dialysis Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top